In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease

High-resolution structural information of membrane-bound α-synuclein provides insight into the MoA of the anti-Parkinson drug UCB0599

(2023) Thomas C. Schwarz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Virtual exam for Parkinson’s disease enables frequent and reliable remote measurements of motor function

(2022) Maximilien Burq et al.   npj Digital Medicine

Phase 1/1b Studies of UCB0599 , an Oral Inhibitor of α‐Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease

(2022) Johan Willem Smit et al.   MOVEMENT DISORDERS

Outcome Assessment in Parkinson Disease Prevention Trials

(2022) Anat Mirelman et al.   NEUROLOGY

Trial of Prasinezumab in Early-Stage Parkinson’s Disease

(2022) Gennaro Pagano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trial of Cinpanemab in Early Parkinson’s Disease

(2022) Anthony E. Lang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

(2022) Timothy M. Miller et al.   NEW ENGLAND JOURNAL OF MEDICINE

Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective

(2021) Diane Stephenson et al.   Journal of Parkinsons Disease

NPT520-34 improves neuropathology and motor deficits in a transgenic mouse model of Parkinson’s disease

(2021) Asma Khan et al.   BRAIN

The Prion-Like Spreading of Alpha-Synuclein in Parkinson’s Disease: Update on Models and Hypotheses

(2021) Asad Jan et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Disease modification and biomarker development in Parkinson disease

(2020) Alberto J. Espay et al.   NEUROLOGY

A roadmap for implementation of patient‐centered digital outcome measures in Parkinson's disease obtained using mobile health technologies

(2019) Alberto J. Espay et al.   MOVEMENT DISORDERS

Transmission of α-synuclein seeds in neurodegenerative disease: recent developments

(2019) Richard J. Karpowicz et al.   LABORATORY INVESTIGATION

Spreading of alpha‐synuclein – relevant or epiphenomenon?

(2019) Bryan A. Killinger et al.   JOURNAL OF NEUROCHEMISTRY

Promising disease-modifying therapies for Parkinson’s disease

(2019) Valina L. Dawson et al.   Science Translational Medicine

Release and uptake of pathologic alpha-synuclein

(2018) Veselin Grozdanov et al.   CELL AND TISSUE RESEARCH

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease

(2018) Joseph Jankovic et al.   JAMA Neurology

The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease

(2018) Diana L. Price et al.   Scientific Reports

A Proposed Roadmap for Parkinson’s Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein

(2018) Kalpana M. Merchant et al.   Journal of Parkinsons Disease

Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues

(2017) Joseph Classen et al.   JOURNAL OF NEURAL TRANSMISSION

A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein

(2017) Franziska Richter et al.   Neurotherapeutics

Ade novocompound targeting α-synuclein improves deficits in models of Parkinson’s disease

(2016) Wolfgang Wrasidlo et al.   BRAIN

Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology

(2016) Trevor Tyson et al.   JOURNAL OF NEUROCHEMISTRY

First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers

(2016) Dale B. Schenk et al.   MOVEMENT DISORDERS

Autosomal dominant Parkinson's disease caused by SNCA duplications

(2016) Takuya Konno et al.   PARKINSONISM & RELATED DISORDERS

Mutations associated with familial Parkinson’s disease alter the initiation and amplification steps of α-synuclein aggregation

(2016) Patrick Flagmeier et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson’s Disease/Dementia with Lewy Bodies

(2016) Diana L. Price et al.   Scientific Reports

Alpha-synuclein spreading in Parkinson’s disease

(2014) Ariadna Recasens et al.   Frontiers in Neuroanatomy

Axonopathy in an α-Synuclein Transgenic Model of Lewy Body Disease Is Associated with Extensive Accumulation of C-Terminal–Truncated α-Synuclein

(2013) Dora Games et al.   AMERICAN JOURNAL OF PATHOLOGY

Alpha-synuclein Post-translational Modifications as Potential Biomarkers for Parkinson Disease and Other Synucleinopathies

(2013) Adrien W. Schmid et al.   MOLECULAR & CELLULAR PROTEOMICS

A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (“Line 61”) Mice

(2012) Marie-Francoise Chesselet et al.   Neurotherapeutics

Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein

(2011) Hoa A. Lam et al.   JOURNAL OF NEUROSCIENCE RESEARCH

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease

(2011) Klaus Seppi et al.   MOVEMENT DISORDERS

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

(2011) Susan H. Fox et al.   MOVEMENT DISORDERS

α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

(2011) Tim Bartels et al.   NATURE

Protein aggregate spreading in neurodegenerative diseases: Problems and perspectives

(2011) Seung-Jae Lee et al.   NEUROSCIENCE RESEARCH

A soluble  -synuclein construct forms a dynamic tetramer

(2011) W. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Proteinase K-resistant α-synuclein is deposited in presynapses in human Lewy body disease and A53T α-synuclein transgenic mice

(2010) Kunikazu Tanji et al.   ACTA NEUROPATHOLOGICA